Promising drug cocktail aims to wipe out breast cancer before surgery
NCT ID NCT07466303
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial will test a combination of two drugs—serplulimab (an immunotherapy) and SHR-A1811 (a targeted chemotherapy)—given before surgery to women with early-stage triple-negative breast cancer. The main goal is to see how many patients have no cancer left at the time of surgery. About 84 women will take part. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
serplulimab (an immunotherapy drug) and SHR-A1811 (a targeted chemotherapy drug)
What this could lead to
If successful, this combination could become a new pre-surgery treatment option for triple-negative breast cancer, potentially increasing the chance of eliminating all cancer before surgery.
What could go wrong
This is a small, early-phase trial with no control group, so results may not be definitive. Side effects from the drug combination are possible and not yet fully known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the First Affiliated Hospital of the Air Force Medical University
Xi'an, 710032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••